FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897721799> ?p ?o ?g. }

• W2897721799 abstract "Hippocampal atrophy is associated with progression in Alzheimer disease (AD). The Critical Path for Alzheimer's Disease (CPAD) consortium is pursuing FDA qualification of baseline intracranial volume-adjusted hippocampal volume (ICV-HV) as an enrichment biomarker in clinical trials targeting mild cognitive impairment (MCI). Hence, the association between ICV-HV and disease progression was assessed using the Clinical Dementia Rating Scale Sum-of-Boxes (CDR-SB). Data: Subject-level data from three sources – the Alzheimer's Disease Neuroimaging Initiative (ADNI)-1 and ADNI-2 observational studies, and the Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx) trial placebo arm – yielded a total of 1,051 aMCI subjects with 7,860 CDR-SB time points in the screening-to-48 months interval. The statistical model used ADNI-1/-2 (N=702), and InDDEx was reserved for external validation. Statistical Modeling: The time course of CDR-SB was described by a non-linear mixed-effects repeated measures model. Covariates were: baseline ICV-HV, sex, baseline mini-mental-state-examination (MMSE), baseline age, and apolipoprotein-E-encoding gene (APOE4) genotype. ICV-HV enrichment was compared between two image analysis algorithms (LEAP™ and FreeSurfer™). Monte Carlo clinical trial simulations were performed to compare the statistical power by sample size in trials with(out) ICV-HV enrichment. Non-enriched trials included subjects sampled from the whole distribution of ICV-HV in the analysis dataset. Enriched trials sampled subjects from truncated ICV-HV distributions based on different cut-off values. A hypothetical drug effect of 50% reduction in progression rate was assumed. In a generalized logistic model, accounting for all covariate effects, a 1 cm3 decrease in baseline ICV-HV was associated with a more than 50% increase in CDR-SB progression rate. In a simulated 24-month placebo-controlled parallel group clinical trial, ICV-HV enrichment yielded meaningful reduction in trial size, ∼63%, ∼35%, and ∼25%, respectively, when including only subjects with baseline ICV-HV lower than the 50th (median), 84.1th (+1 standard deviation, SD), and 97.7th (+2 SD) percentile of the ICV-HV distribution. The sample size savings between LEAP™ and FreeSurfer™ were similar (within 6-to-8% of each other). External validation with InDDEx is ongoing. ICV-HV serves as a prognostic indicator of MCI clinical progression, with utility to optimize the sample size to demonstrate the drug effects in clinical trials." @default.
• W2897721799 created "2018-10-26" @default.
• W2897721799 creator A5010643874 @default.
• W2897721799 creator A5012892785 @default.
• W2897721799 creator A5016439888 @default.
• W2897721799 creator A5019844576 @default.
• W2897721799 creator A5024585813 @default.
• W2897721799 creator A5024807342 @default.
• W2897721799 creator A5024979557 @default.
• W2897721799 creator A5033328565 @default.
• W2897721799 creator A5033764099 @default.
• W2897721799 creator A5036259423 @default.
• W2897721799 creator A5038929743 @default.
• W2897721799 creator A5042508284 @default.
• W2897721799 creator A5045300839 @default.
• W2897721799 creator A5050176243 @default.
• W2897721799 creator A5058044307 @default.
• W2897721799 creator A5064405735 @default.
• W2897721799 creator A5071233755 @default.
• W2897721799 creator A5072891453 @default.
• W2897721799 creator A5084865929 @default.
• W2897721799 creator A5086549440 @default.
• W2897721799 date "2018-07-01" @default.
• W2897721799 modified "2023-10-16" @default.
• W2897721799 title "P3‐031: THE CRITICAL PATH FOR ALZHEIMER'S DISEASE: HIPPOCAMPAL VOLUME AS AN ENRICHMENT BIOMARKER IN TRIALS OF PATIENTS WITH MILD COGNITIVE IMPAIRMENT" @default.
• W2897721799 doi "https://doi.org/10.1016/j.jalz.2018.06.1386" @default.
• W2897721799 hasPublicationYear "2018" @default.
• W2897721799 type Work @default.
• W2897721799 sameAs 2897721799 @default.
• W2897721799 citedByCount "0" @default.
• W2897721799 crossrefType "journal-article" @default.
• W2897721799 hasAuthorship W2897721799A5010643874 @default.
• W2897721799 hasAuthorship W2897721799A5012892785 @default.
• W2897721799 hasAuthorship W2897721799A5016439888 @default.
• W2897721799 hasAuthorship W2897721799A5019844576 @default.
• W2897721799 hasAuthorship W2897721799A5024585813 @default.
• W2897721799 hasAuthorship W2897721799A5024807342 @default.
• W2897721799 hasAuthorship W2897721799A5024979557 @default.
• W2897721799 hasAuthorship W2897721799A5033328565 @default.
• W2897721799 hasAuthorship W2897721799A5033764099 @default.
• W2897721799 hasAuthorship W2897721799A5036259423 @default.
• W2897721799 hasAuthorship W2897721799A5038929743 @default.
• W2897721799 hasAuthorship W2897721799A5042508284 @default.
• W2897721799 hasAuthorship W2897721799A5045300839 @default.
• W2897721799 hasAuthorship W2897721799A5050176243 @default.
• W2897721799 hasAuthorship W2897721799A5058044307 @default.
• W2897721799 hasAuthorship W2897721799A5064405735 @default.
• W2897721799 hasAuthorship W2897721799A5071233755 @default.
• W2897721799 hasAuthorship W2897721799A5072891453 @default.
• W2897721799 hasAuthorship W2897721799A5084865929 @default.
• W2897721799 hasAuthorship W2897721799A5086549440 @default.
• W2897721799 hasConcept C105795698 @default.
• W2897721799 hasConcept C118552586 @default.
• W2897721799 hasConcept C126322002 @default.
• W2897721799 hasConcept C129848803 @default.
• W2897721799 hasConcept C143998085 @default.
• W2897721799 hasConcept C15744967 @default.
• W2897721799 hasConcept C185592680 @default.
• W2897721799 hasConcept C2778373026 @default.
• W2897721799 hasConcept C2779134260 @default.
• W2897721799 hasConcept C2779483572 @default.
• W2897721799 hasConcept C2780906993 @default.
• W2897721799 hasConcept C2781197716 @default.
• W2897721799 hasConcept C33923547 @default.
• W2897721799 hasConcept C502032728 @default.
• W2897721799 hasConcept C535046627 @default.
• W2897721799 hasConcept C55493867 @default.
• W2897721799 hasConcept C58693492 @default.
• W2897721799 hasConcept C71924100 @default.
• W2897721799 hasConceptScore W2897721799C105795698 @default.
• W2897721799 hasConceptScore W2897721799C118552586 @default.
• W2897721799 hasConceptScore W2897721799C126322002 @default.
• W2897721799 hasConceptScore W2897721799C129848803 @default.
• W2897721799 hasConceptScore W2897721799C143998085 @default.
• W2897721799 hasConceptScore W2897721799C15744967 @default.
• W2897721799 hasConceptScore W2897721799C185592680 @default.
• W2897721799 hasConceptScore W2897721799C2778373026 @default.
• W2897721799 hasConceptScore W2897721799C2779134260 @default.
• W2897721799 hasConceptScore W2897721799C2779483572 @default.
• W2897721799 hasConceptScore W2897721799C2780906993 @default.
• W2897721799 hasConceptScore W2897721799C2781197716 @default.
• W2897721799 hasConceptScore W2897721799C33923547 @default.
• W2897721799 hasConceptScore W2897721799C502032728 @default.
• W2897721799 hasConceptScore W2897721799C535046627 @default.
• W2897721799 hasConceptScore W2897721799C55493867 @default.
• W2897721799 hasConceptScore W2897721799C58693492 @default.
• W2897721799 hasConceptScore W2897721799C71924100 @default.
• W2897721799 hasIssue "7S_Part_20" @default.
• W2897721799 hasLocation W28977217991 @default.
• W2897721799 hasOpenAccess W2897721799 @default.
• W2897721799 hasPrimaryLocation W28977217991 @default.
• W2897721799 hasRelatedWork W1540168105 @default.
• W2897721799 hasRelatedWork W1997526132 @default.
• W2897721799 hasRelatedWork W2048674585 @default.
• W2897721799 hasRelatedWork W2075528565 @default.
• W2897721799 hasRelatedWork W2139523469 @default.
• W2897721799 hasRelatedWork W2766152896 @default.
• W2897721799 hasRelatedWork W2804922289 @default.
• W2897721799 hasRelatedWork W2902622269 @default.
• W2897721799 hasRelatedWork W2998575611 @default.

• next